P olypharmacy and inappropriate prescribing of medications are an increasing problem in elderly adults. Drugrelated admissions for people aged 65 to 84 increased by 96% from 1997 to 2008, 1 and nearly half of adverse drug event-related hospitalizations occur in adults aged 80 and older. 2 Inappropriate medications in elderly adults can lead to confusion, falls, cognitive impairment, poor health status, and mortality. [3] [4] [5] [6] [7] The rapidly growing population of persons aged 65 and older 8 will only magnify these hazards unless more attention is focused on understanding and improving medication management and reconciliation.
In the lexicon of inappropriate prescribing, two important terms are potentially inappropriate medications (PIMs) and actually inappropriate medications (AIMs). PIMs are medications that-in light of their pharmacological effects and prior research-are deemed potentially harmful to an elderly adult; when a drug is labeled a PIM, no consideration is given to its potential benefits or the clinical circumstances surrounding its prescription for an individual, but a PIM can further be classified as an AIM if the risk of harm from the drug is judged to outweigh the potential clinical benefit after an individual's clinical circumstances are considered. Approximately 50% of hospitalized elderly adults are discharged on at least one PIM, and approximately 80% of these individuals are discharged on at least one AIM. [9] [10] [11] [12] Although PIMs and AIMs may be identified at the time of hospital discharge, the intensive care unit (ICU) is often where these medications are first prescribed. The fastestgrowing group of individuals treated in the ICU is elderly adults, 13 a vulnerable population frequently given PIMs and AIMs in the hospital. It was recently found that 85% of elderly ICU survivors were discharged from the hospital on at least one PIM and that 51% were discharged on at least one AIM.
14 Of individuals with one or more PIMs at hospital discharge, 59% had at least one AIM.
14 Fifty-percent of PIMs and 59% of AIMs are first prescribed in the ICU. 14 In this particularly complex population, many PIMs are reasonably appropriate given the individual's clinical conditions (the PIMs are not AIMs). Concordance or discordance of PIMs and AIMs has significant implications. For example, if drug class "A" accounts for a substantial proportion of PIMs in older ICU survivors, but the majority of these PIMs are appropriately prescribed given the individuals' circumstances, an intervention aimed at decreasing all PIMs will have the unintended consequence of reducing use of some appropriate medications. A more-focused approach is to reduce exposure to AIMs by addressing the location in the hospital where AIMs are most commonly initiated, targeting classes of PIMs that are most often judged to be actually inappropriate after consideration of individual's circumstances, and targeting individuals most likely to receive AIMs and providers most likely to prescribe them. The risk factors for prescription of AIMs in elderly adults surviving an ICU hospitalization are currently unknown.
This study extends previous work that described the prevalence of PIMs and AIMs in critically ill elderly adults 14 and explores which specific PIM categories at hospital discharge were most often considered AIMs, where specific AIM categories were most often initiated (before the hospital, a pre-ICU ward, ICU, or a post-ICU ward), and risk factors for PIMs and AIMs at hospital discharge. It was hypothesized that opiates, sedatives, and antipsychotics would be the PIMs that were most often AIMs in older ICU survivors and that older adults with delirium (which may prompt initiation of sedatives or antipsychotics) are at highest risk to be discharged from the hospital on PIMs and AIMs.
METHODS

Study Design and Population
This prospective cohort study was nested in a larger longterm cohort study (NCT00392795) that enrolled critically ill individuals admitted with respiratory failure or shock to the medical, surgical, or cardiovascular ICU at Vanderbilt University Hospital. Individuals were excluded from the parent study if they were moribund, had respiratory failure or shock for longer than 72 hours before enrollment, were unable or unlikely to participate in cognitive testing during follow-up (because of blindness, deafness, inability to speak English, active substance abuse, or psychotic disorder), or were at high risk for severe cognitive impairment before the time of screening (individuals admitted after cardiopulmonary arrest or with documented acute neurological injury, those with chronic neurological disease that prevented independent living, and those who had undergone cardiac surgery in the 3 months before screening). Only individuals enrolled in the parent study who were aged 60 and older and were discharged alive from the hospital were included in the current study. The age cutoff of 60 was chosen, consistent with previous research, 15 to include individuals at high risk of polypharmacy and inappropriate medication prescribing. Individuals discharged to hospice were excluded because of common use of PIMs for symptom control (i.e., these PIMs are rarely AIMs in the hospice population). Informed consent was obtained from an available surrogate at enrollment in the parent study; individuals provided consent before hospital discharge, after their critical illness had improved and they were deemed competent to consent. The institutional review board at Vanderbilt University approved the study protocol.
Demographics and Clinical Characteristics
Demographic characteristics, Acute Physiology And Chronic Health Evaluation (APACHE) II severity-of-illness score, 16 ICU admission diagnoses, type of ICU, and comorbidities according to the Charlson Comorbidity Index 17 were recorded at study enrollment. Trained research personnel used the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) 18 to assess individuals for delirium daily until hospital discharge or study Day 30. Information on length of stay in the ICU and hospital, discharge location (home vs other), and discharging hospital service (medical vs surgical) was also recorded from the medical record.
Medication Abstraction and Classification
Medical charts (including physician notes and medication administration records) were reviewed to identify PIMs using the 2003 Beers criteria, 19 which were supplemented with additional medications identified by reviewing the medication safety literature published since 2003, 6, [20] [21] [22] considering articles reporting the association between medication prescription, adverse events, and medication safety in elderly adults. Although a formal review with the Delphi approach was not completed, an evidence-based approach was applied to the selection of these medications, as suggested in the Institute of Medicine standards for practice guidelines (http://www.iom.edu/Reports/2011/ClinicalPractice-Guidelines-We-Can-Trust.aspx) and as used in the recent Beers update. 23 Most of the medications included in the list have been added to the updated Beers Criteria. 23 A clinical panel comprising a hospitalist (EEV), a geriatrician (LS), and a clinical pharmacist (EN) reviewed all PIMs at hospital discharge to identify AIMs. Similar to an approach used previously, 15 the panel reviewed hospital discharge medications, participant medical history, and laboratory data to determine whether each discharge PIM was actually inappropriate (an AIM) based on the clinical circumstances of the individual. A PIM was considered an AIM when at least two of the three panel members considered its risk-benefit profile to be unfavorable based on the individual's specific circumstances and criteria specified in the Medication Appropriateness Index, 4, 24 including indication, dosage, and likely effectiveness, as well as drug-drug interactions, drug-disease interactions, unnecessary duplication, and duration of treatment. A medication did not need to have caused harm to be considered an AIM. This approach was designed to mirror multidisciplinary clinical decision-making on rounds as opposed to independent assessments by individual clinicians, so agreement between individual clinicians was not calculated.
Each PIM and AIM was classified into one of the following 12 mutually exclusive categories based on medication class and side effects: benzodiazepines, nonbenzodiazepine sedatives, typical antipsychotics, atypical antipsychotics, opioids, anticholinergics, antidepressants, drugs causing orthostasis, nonsteroidal antiinflammatory drugs, antiarrhythmics, muscle relaxants, and others. A complete list of medications reviewed, according to their classification, is available in Appendix S1.
To determine where specific types of AIMs were initiated, medications were abstracted from the medical record at five distinct time points-before admission (outpatient medications recorded at the time of admission), ward admission (outpatient medications continued at admission plus newly prescribed inpatient medications), ICU admission, ICU discharge, and hospital discharge.
Statistical Analysis
Participant demographic and clinical variables were summarized using medias and interquartile ranges for continuous variables and proportions for categorical variables. PIMs and AIMs were described as the total number prescribed in all participants at different time points. For each discharge PIM category, the percentage of PIMs that were determined to be AIMs were calculated, and this was considered to be the positive predictive value (PPV) for that PIM category; PIMs with higher PPVs could be useful when screening for possible AIMs (yielding more true positives), whereas PIMs with lower PPVs would yield more false positives (PIMs that were appropriately prescribed).
Multivariable Poisson regression models with generalized estimating equations were used to analyze risk factors for the number of PIMs and AIMs per participant at discharge. PIMs and AIMs were analyzed as the number prescribed per participant (continuous variables) rather than as present or absent (dichotomous variables) to preserve statistical power. Age, number of preadmission PIMs, Charlson comorbidity score, total days of delirium, hospital length of stay, discharge disposition (home or not home), and discharge service (medical or surgical), determined a priori according to prior publications 9, 25 and clinical relevance, were included in both models. All covariates were included in both models, regardless of statistical significance. R (version 2.11.1, www.r-project.org) was used for all statistical analyses. Two-sided P < .05 was considered statistically significant.
RESULTS
One hundred thirty-five participants enrolled in the parent study between May 2008 and 2010 who were aged 60 and older and were discharged alive from the hospital were identified; 11 of these were discharged to hospice, and four withdrew from the study before discharge. The remaining 120 participants were included in the current study and are described in Table 1 . The cohort had a median age of 68 years, and nearly one in four participants was 75 years of age or older. A median APACHE score of 27 indicated a high severity of illness, and comorbid illness was common.
Categories of PIMs and AIMs: Frequency at Discharge and Time of Initiation
A total of 250 PIMs were prescribed at discharge. The four most common types of PIMs at discharge were opioids, anticholinergic medications, antidepressants, and drugs causing orthostasis ( Table 2) . Ninety of the 250 discharge PIMs (36%) were classified as AIMs, with the three most common types being anticholinergics, nonbenzodiazepine hypnotics (e.g., zolpidem), and opioids (Table 2) . Of the anticholinergic AIMs, the histamine blockers (61%) and promethazine (15%) were the most common. Three of the four most commonly prescribed discharge PIM categories had low PPVs (i.e., these PIMs were infrequently classified as AIMs). Specifically, 16% of opioids, 23% of antidepressants, and 10% of drugs causing orthostasis were found to be actually inappropriate after the individual's circumstances were considered. Discharge PIM categories with the highest PPV for AIMs included the anticholinergics (55%), nonbenzodiazepine hypnotics (67%), benzodiazepines (67%), atypical antipsychotics (71%), and muscle relaxants (100%; Table 2 ). Appendix S2 shows the distribution of PIM and AIM categories at the participant level.
Of the AIMs most often prescribed at hospital discharge, 67% of anticholinergic AIMs were initiated in the ICU, 21% were started on the wards, and 12% were present before admission. Of the nonbenzodiazepine hypnotic AIMs, 46% were initiated in the ICU, 23% were started on the wards, and 31% were present before admission. Of the opioids determined to be AIMs, 73% were initiated in the ICU, 18% were started on the wards, and 9% were present before admission. Four of every five atypical antipsychotics classified as AIMs were started in the ICU, 20% were initiated on the ward, and none were present before admission. Certain offending medications were initiated almost exclusively in the hospital. For example, only 1% of participants (1/120) were receiving an atypical antipsychotic before admission and 12% (14/ 120) were discharged from the hospital on an atypical antipsychotic.
PIMs and AIMs: Risk Factors for Number at Discharge
In a multivariable analysis, the number of preadmission PIMs (P < .001), discharge to somewhere other than home (P = .03), and discharge from a surgical service (P < .001) were found to be significant independent predictors of the number of PIMs prescribed to an individual at hospital discharge (Table 3 ), but none of the factors examined were associated with the number of AIMs at hospital discharge. Neither age (P = .90), number of preadmission PIMs (P = .49), Charlson comorbidity score (P = .96), delirium duration (P = .68), hospital length of stay (P = .15), discharge disposition (P = .72), nor discharge service (P = .08) predicted number of discharge AIMs. 
DISCUSSION
Medications are the primary cause of adverse events for elderly adults after hospital discharge. 6, 20 Significant attention has been focused on reducing prescription of PIMs, but some of these medications are appropriately prescribed to individuals with complicated health status, who are likely to benefit from them. Thus, attention should be directed specifically toward reducing AIMs. This study found that three of the most commonly prescribed types of PIMs (opioids, antidepressants, and drugs causing orthostasis) were often judged to be appropriate after considering the individual's clinical condition (e.g., postoperative pain control, a new diagnosis of major depressive disorder). These PIM categories, therefore, had low PPV for detecting AIMs in older survivors of critical illness. In addition, the risk factors for being prescribed a PIM at discharge were not necessarily risk factors for being prescribed an AIM. This study, the first to specifically evaluate ICU survivors for receipt of PIMs and AIMs, suggests that published lists of PIMs may not be an efficient screening tool for identifying and thereby reducing prescription of AIMs to older adults after critical illness. Instead, a more-refined list of PIMs with high PPV is needed, as is knowledge regarding risk factors for receipt of AIMs after critical illness.
A critical feature of the investigation was a thorough evaluation of the actual appropriateness of each PIM based on the clinical circumstances. It was recently emphasized that studies of PIMs should determine scenarios in which it is appropriate to prescribe PIMs, moving beyond simply labeling some medications as "potentially inappropriate," because some PIMs are appropriately prescribed in specific clinical situations. 26 Clinicians caring for older adults, especially at the end of a complex hospital stay, must determine which PIMs should be discontinued before hospital discharge and which are appropriately prescribed.
The finding that some common PIMs were rarely AIMs has significant implications. If one views a list of PIMs as a screening tool, any given item (e.g., medication class) on the list has 100% sensitivity for detecting an AIM in that medication class and 100% negative predictive value (NPV) for excluding AIMs in that class. (In general, the NPV is defined as the percentage of subjects with a negative test result who are correctly diagnosed.) Unfortunately, some items on the screening tool will have low PPV for the identification of an AIM (e.g., opiates in this cohort), whereas others will have high PPV (e.g., atypical antipsychotics in this cohort). This study shows that the PPV depends on the drug type. Thus, when developing a screening system, one cannot be concerned only with high NPV, one must consider PPV as well. Screening tools that include medication classes with low PPV will generate false-positive "flags" or warnings, which could lead to misguided clinical decisions or alert fatigue. 27 In the current cohort, for example, if clinicians were alerted to each opiate prescription at the time of discharge, this may have led to inappropriate discontinuation of an appropriate medicine needed for pain control, change to a potentially more-harmful alternative, and a decrease of the effect of such alerts regarding PIMs that have much higher PPVs for being AIMs. It is likely that electronic warning systems will be valuable in reducing AIMs after critical illness, but the systems that rely on PIMs as screening tools should include only those with the highest PPV, which in the current study were the atypical antipsychotics (71%), nonbenzodiazepine hypnotics (67%), benzodiazepines (67%), anticholinergics (55%), and muscle relaxants (100%).
The fact that many PIMs are not AIMs also reveals the value of using a multidisciplinary team to identify AIMs from lists of PIMs generated when discharge medication lists are screened. In this study, a team was created with a geriatrician, internist, and pharmacist, all of whom are often involved in the care of elderly hospitalized adults. 28 Whereas a computer-based decision support system can easily identify PIMs using structured data, 29 evaluating the clinical context is far more complicated, especially for older ICU survivors. Thus, a multidisciplinary team is needed to consider the clinical context to distinguish PIMs from AIMs. Such a team is not available in some settings; when resources are limited, knowledge of which PIMs are most likely AIMs (have high PPVs) could guide the development of computer-based decision support systems or other surveillance approaches that are efficient in that particular setting.
Interventions designed to reduce AIMs need not be implemented solely at the time of hospital discharge. Nearly two of every three AIMs were first prescribed in the ICU, a time during which the medication may have been appropriately given. For example, nonbenzodiazepine sedatives (e.g., zolpidem, choral hydrate) and atypical antipsychotics are frequently used in the ICU because delirium and sleep cycle alteration are common complications of critical illness. 30, 31 Even though these and other PIMs may be appropriate early in the ICU course, the indications for their use are usually temporary. Failing to discontinue such medications before hospital discharge is potentially harmful in the long-term. 32, 33 Thus, clinicians should seek to identify and discontinue AIMs at three important transitions during a critically ill elderly adult's hospital course. Clinicians should review medication appropriateness at the time of hospital or ICU admission. Another evaluation should be performed at the time of ICU discharge. Finally, medications should be screened for PIMs at hospital discharge, and the individual's clinical situation should be reviewed, ideally by a multidisciplinary team of clinicians, to judge the appropriateness of each PIM. Electronic health records could be leveraged to alert clinicians at each of these times to the presence of PIMs, particularly those with high PPVs for being AIMs.
Strategies designed to reduce AIMs would be more focused if the specific individuals most likely to receive AIMs or the providers most likely to prescribe them were known. In this small study, it was not possible to demonstrate significant risk factors associated with the number of AIMs at discharge; thus, additional research is needed to target AIM-reducing interventions. Although no risk factors were found for AIMs, it was found that a large number of preadmission PIMs, discharge to a location other than home, and discharge from a surgical service were are all predictive of a large number of PIMs at discharge. These risk factors have been found in other studies as well. 9, 25, 34 The fact that PIM risk factors were not associated with AIMs highlights, once again, that interventions designed to identify PIMs will not always efficiently iden-tify AIMs. A particular PIM category (e.g., opioids) that the clinical panel usually deemed appropriate given the clinical circumstances (e.g., treatment of postoperative pain) may have driven some of the factors that independently predicted PIMs (e.g., discharge from a surgical service). In these situations, it is likely that the PIM risk factors are associated with the indications that led to appropriate prescription and continuation of the PIMs. Risk factors specific to AIMs rather than PIMs are therefore needed to shape efficient interventions. A smaller sample size of AIMs may have hampered the ability to identify risk factors, because that reduced statistical power. Larger, multicenter investigations may therefore still identify risk factors for AIMs. Until such factors are known, efforts to reduce AIMs should focus on the PIM categories that are almost always inappropriate at discharge (those with high PPVs), such as atypical antipsychotics, nonbenzodiazepine hypnotics, benzodiazepines, anticholinergics, and muscle relaxants.
An association between delirium days, PIMs, and AIMs had been hypothesized. The nature of the statistical analysis, which examined potential predictors of PIMs and AIMs overall, may explain the lack of such a relationship. Delirium duration might be associated with greater prescription of specific PIMs or AIMs, such as antipsychotics or benzodiazepines, but the sample size was too small to examine predictors of specific PIM or AIM types. Future studies with larger samples should evaluate this question further.
One limitation of this study is that the short-and long-term adverse clinical outcomes (e.g., functional and cognitive status, rehospitalization, institutionalization) related to AIM prescription were not evaluated. Ultimately, development of an evidence base that specifies the likelihood of harm associated with different medications, under different clinical circumstances, would provide detailed guidance to providers about the relative risks and benefits of particular agents in elderly adults. Such a knowledge base could be incorporated into computerized order entry systems and drug safety surveillance programs. Further studies are needed to link PIMs and AIMs to adverse events so that such systems can be developed.
This study has several other limitations. First, only prescribed medications, and not the cohort, were examined for inappropriate underprescribing or medication discontinuation, any of which can expose individuals to risk, as recently highlighted. 35 Second, the single-center nature of this study limits generalizability of the results to populations similar to the one studied. Third, this study was performed before the 2012 Beers update was published. 23 The majority of the medications added to the 2003 Beers criteria based on a review of the medication safety literature 6, 20, 21 have also been included in the 2012 update, supporting the approach of the current study, but some of the medications may require further deliberation before widely being considered PIMs. Fourth, owing to the multidisciplinary adjudication process used, agreement between individual clinicians in the panel regarding their determination of AIMs was not assessed. It is possible that biases within the panel (e.g., personality or hierarchical relationships) influenced determinations, although an attempt was made to minimize this by the selection of individuals (who were approximately the same age and did not have dominating personalities) and requirement for agreement between at least two of three adjudicators. Fifth, the effect of each clinical discipline (e.g. cardiology, nephrology, orthopedics, etc.) on the risk of prescribing PIMs and AIMs was not specifically evaluated; this should be further evaluated.
In summary, PIMs (medications often associated with adverse effects) prescribed to elderly adults at hospital discharge were common and most often initiated during their ICU stay. Most of these PIMs were considered appropriate upon clinical review, which may explain why risk factors were identified for PIMs at discharge but not for AIMs. That many PIMs were not AIMs highlights the importance of clinical context in assessing the safety of medications at discharge. If medication safety programs focus on reducing AIMs rather than PIMs (e.g., by screening primarily PIMs with high PPV for AIMs), they may save time and money by avoiding unnecessary scrutiny of medications that are appropriately prescribed and focusing attention on higherrisk medications.
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